ORAL SMALL MOLECULES
Integrated endothelial restoration
Phenotype-led oral medicines for multifactorial vascular dysfunction.
Curacle proprietary · SOLVADYS®
Restoring Microvessels,
Redefining Health
Curacle develops first-in-class therapies restoring microvascular function
in aging
and chronic diseases.
OUR TECHNOLOGY
Two development engines.
One vascular strategy.
Curacle pairs phenotype-led oral medicines with vascular-targeted biologics to address complex endothelial dysfunction at complementary levels.
VASCULAR-TARGETED BIOLOGICS
Precision vascular signaling
Engineered antibody biologics for defined disease-driving pathways.
Co-developed with MabTics · EAGLES®-enabled
THE PIPELINE
Oral Small Molecule
CU06 (Rivasterat)
Diabetic macular edema (DME)
An oral candidate designed to restore endothelial function in diabetic macular edema (DME). Preparations for Phase 2b are underway.
READ MORE
Oral Small Molecule
CU01
Diabetic nephropathy
An oral candidate combining NRF2 activation and TGF-β inhibition for diabetic nephropathy. Phase 2b completed in Korea.
READ MORE
Monoclonal Antibody
MT-101
Acute kidney injury & chronic kidney disease
A Tie2 agonist antibody designed to stabilize blood vessels and protect kidney function in acute kidney injury and chronic kidney disease.
READ MORE
Bispecific Antibody
MT-103 (MMT-205)
Retinal diseases
A bispecific antibody combining Tie2 activation and VEGF inhibition for retinal diseases. Globally licensed to Memento Medicines.
READ MORE
Monoclonal Antibody
MT-201
Thrombotic diseases
A PDI-targeting antibody designed to inhibit pathological blood clot formation for the treatment of thrombotic diseases.
READ MORE
Bispecific Antibody
MT-202
Ischemic stroke
A bispecific antibody combining PDI inhibition and Tie2 activation, designed to address thrombosis and protect vascular integrity in ischemic stroke.
READ MORE
-
Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases
-
Curacle Receives Upfront Payment from Global Licensing Deal for MT-103
-
Curacle Shares Rise for Second Straight Day on Up to 1.6 Trillion Won Licensing Deal